Diagnostic performance of 18 F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.

MLA

Teyateeti, Ajalaya, et al. “Diagnostic Performance of 18 F-Fluciclovine PET/CT in Prostate Cancer Patients with Rising PSA Level ≤ 0.5 Ng/Ml after Multiple Treatment Failures.” American Journal of Nuclear Medicine and Molecular Imaging, vol. 11, no. 2, Apr. 2021, pp. 87–98. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=34079638&authtype=sso&custid=ns315887.

APA

Teyateeti, A., Teyateeti, A., Ravizzini, G. C., Xu, G., Tang, C., Tu, S.-M., Macapinlac, H. A., & Lu, Y. (2021). Diagnostic performance of 18 F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures. American Journal of Nuclear Medicine and Molecular Imaging, 11(2), 87–98.

Chicago

Teyateeti, Ajalaya, Achiraya Teyateeti, Gregory C Ravizzini, Guofan Xu, Chad Tang, Shi-Ming Tu, Homer A Macapinlac, and Yang Lu. 2021. “Diagnostic Performance of 18 F-Fluciclovine PET/CT in Prostate Cancer Patients with Rising PSA Level ≤ 0.5 Ng/Ml after Multiple Treatment Failures.” American Journal of Nuclear Medicine and Molecular Imaging 11 (2): 87–98. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=34079638&authtype=sso&custid=ns315887.